Bifrost Medicines · Precision Oncology
Precision medicine.
Focused on leukemia.
We are developing small-molecule medicines for genetically defined cancers, starting with inv(16) acute myeloid leukemia.
Discover our program
- Our focus
- inv(16) AML
- Lead program
- BFM-041
- Development
- Preclinical
Our approach
Targeting the biology
that drives leukemia.
Bifrost Medicines is a biotechnology company focused on precision oncology. Our aim is to develop medicines that act on the specific molecular drivers of cancer.
Our lead candidate, BFM-041, is designed to disrupt the interaction between the CBFβ-SMMHC fusion protein and RUNX1 in inv(16) acute myeloid leukemia (AML).
We are advancing preclinical research to evaluate its potential as a targeted treatment.
Scientific foundation
Built on published research.
Our program builds on research with the predecessor compound AI-10-49, reported in Science and Cell. These studies support the scientific rationale for targeting CBFβ-SMMHC.
Scientific guidance
John H. Bushweller, PhD
Senior Scientific Advisor
Professor at the University of Virginia and a co-developer of AI-10-49, with expertise in the molecular mechanisms of leukemia.
Contact
Connect with Bifrost.
For scientific, partnership and company inquiries.